Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant Pharma (VRX) 1Q16 Was A Clean-Up Quarter - Guggenheim
June 8, 2016 6:57 AM EDTGuggenheim analyst, Louise Chen, defended Valeant Pharmaceuticals (NYSE: VRX) as she continues to believe that VRX's long-term growth prospects are underappreciated. Upside to expectations could come from: 1) divestment of non-core products to pay down debt; 2) meeting or beating quarterly earnings in '16; and, 3)... More
